These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1411 related items for PubMed ID: 28079894

  • 1. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.
    Jin F, Wang Y, Li M, Zhu Y, Liang H, Wang C, Wang F, Zhang CY, Zen K, Li L.
    Cell Death Dis; 2017 Jan 12; 8(1):e2540. PubMed ID: 28079894
    [Abstract] [Full Text] [Related]

  • 2. MiR-26a-5p Inhibits Cell Proliferation and Enhances Doxorubicin Sensitivity in HCC Cells via Targeting AURKA.
    Yuan YL, Yu H, Mu SM, Dong YD, Li Y.
    Technol Cancer Res Treat; 2019 Jan 01; 18():1533033819851833. PubMed ID: 31570091
    [Abstract] [Full Text] [Related]

  • 3. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 4. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
    Tu C, Chen W, Wang S, Tan W, Guo J, Shao C, Wang W.
    J Cell Mol Med; 2019 Nov 06; 23(11):7190-7199. PubMed ID: 30801960
    [Abstract] [Full Text] [Related]

  • 5. LncRNA HCG11 accelerates the progression of hepatocellular carcinoma via miR-26a-5p/ATG12 axis.
    Li ML, Zhang Y, Ma LT.
    Eur Rev Med Pharmacol Sci; 2019 Dec 06; 23(24):10708-10720. PubMed ID: 31858580
    [Abstract] [Full Text] [Related]

  • 6. miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells.
    Zhou Y, Chen E, Tang Y, Mao J, Shen J, Zheng X, Xie S, Zhang S, Wu Y, Liu H, Zhi X, Ma T, Ni H, Chen J, Chai K, Chen W.
    Cell Death Dis; 2019 Nov 06; 10(11):843. PubMed ID: 31695022
    [Abstract] [Full Text] [Related]

  • 7. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L, Beckebaum S, Iacob S, Wu G, Kaiser GM, Radtke A, Liu C, Kabar I, Schmidt HH, Zhang X, Lu M, Cicinnati VR.
    J Hepatol; 2014 Mar 06; 60(3):590-8. PubMed ID: 24211739
    [Abstract] [Full Text] [Related]

  • 8. MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3.
    Zhao N, Wang R, Zhou L, Zhu Y, Gong J, Zhuang SM.
    Mol Cancer; 2014 Feb 24; 13():35. PubMed ID: 24565101
    [Abstract] [Full Text] [Related]

  • 9. MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2.
    Ma DN, Chai ZT, Zhu XD, Zhang N, Zhan DH, Ye BG, Wang CH, Qin CD, Zhao YM, Zhu WP, Cao MQ, Gao DM, Sun HC, Tang ZY.
    J Hematol Oncol; 2016 Jan 06; 9():1. PubMed ID: 26733151
    [Abstract] [Full Text] [Related]

  • 10. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.
    Cao F, Yin LX.
    Exp Mol Pathol; 2019 Feb 06; 106():34-43. PubMed ID: 30539797
    [Abstract] [Full Text] [Related]

  • 11. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.
    Tang Y, Chen K, Luan X, Zhang J, Liu R, Zheng X, Xie S, Ke H, Zhang X, Chen W.
    Int J Oncol; 2020 Dec 06; 57(6):1368-1380. PubMed ID: 33174013
    [Abstract] [Full Text] [Related]

  • 12. MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
    Xu H, Zhao L, Fang Q, Sun J, Zhang S, Zhan C, Liu S, Zhang Y.
    PLoS One; 2014 Dec 06; 9(12):e115565. PubMed ID: 25531114
    [Abstract] [Full Text] [Related]

  • 13. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway.
    Yang X, Liang L, Zhang XF, Jia HL, Qin Y, Zhu XC, Gao XM, Qiao P, Zheng Y, Sheng YY, Wei JW, Zhou HJ, Ren N, Ye QH, Dong QZ, Qin LX.
    Hepatology; 2013 Jul 06; 58(1):158-70. PubMed ID: 23389848
    [Abstract] [Full Text] [Related]

  • 14. CircularRNA-9119 protects hepatocellular carcinoma cells from apoptosis by intercepting miR-26a/JAK1/STAT3 signaling.
    Yang L, Xue H, Sun Y, Zhang L, Xue F, Ge R.
    Cell Death Dis; 2020 Jul 30; 11(7):605. PubMed ID: 32732872
    [Abstract] [Full Text] [Related]

  • 15. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
    Li W, Dong X, He C, Tan G, Li Z, Zhai B, Feng J, Jiang X, Liu C, Jiang H, Sun X.
    J Exp Clin Cancer Res; 2019 May 03; 38(1):183. PubMed ID: 31053148
    [Abstract] [Full Text] [Related]

  • 16. Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.
    Lou G, Song X, Yang F, Wu S, Wang J, Chen Z, Liu Y.
    J Hematol Oncol; 2015 Oct 29; 8():122. PubMed ID: 26514126
    [Abstract] [Full Text] [Related]

  • 17. Lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine and siULK1 in hepatocellular carcinoma therapy.
    Wang X, Wu F, Li G, Zhang N, Song X, Zheng Y, Gong C, Han B, He G.
    Acta Biomater; 2018 Jul 01; 74():414-429. PubMed ID: 29787814
    [Abstract] [Full Text] [Related]

  • 18. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
    Jing Z, Ye X, Ma X, Hu X, Yang W, Shi J, Chen G, Gong L.
    Cancer Med; 2020 Jun 01; 9(12):4324-4338. PubMed ID: 32324343
    [Abstract] [Full Text] [Related]

  • 19. miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1.
    Lu L, Zhang D, Xu Y, Bai G, Lv Y, Liang J.
    Biomed Pharmacother; 2018 Aug 01; 104():613-621. PubMed ID: 29803174
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.